Podium to Practice: ESMO® 2025 – Melanoma: Safe Stop Trial
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
LBA61 – Early discontinuation of anti-PD-1 therapy upon achieving a complete or partial response in patients with metastatic melanoma: the multicentre prospective Safe Stop Trial
Studies/trials discussed:
LBA61 – Early discontinuation of anti-PD-1 therapy upon achieving a complete or partial response in patients with metastatic melanoma: the multicentre prospective Safe Stop Trial
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.